Lido Advisors’s CorMedix CRMD Stock Holding History

Lido Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$351K	Sell	44,707 -33	-0.1%	-$261	﹤0.01%	1671
2026 Q1	$304K	Sell	44,740 -1,984	-4%	-$14.7K	﹤0.01%	1558
2025 Q4	$543K	Hold	46,724	–	–	﹤0.01%	1265
2025 Q3	$543K	Sell	46,724 -517	-1%	-$6.25K	﹤0.01%	1202
2025 Q2	$582K	Buy	47,241 +501	+1%	+$5.53K	﹤0.01%	1050
2025 Q1	$288K	Hold	46,740	–	–	﹤0.01%	1233
2024 Q4	$379K	Hold	46,740	–	–	﹤0.01%	1106
2024 Q3	$378K	Buy	46,740 +18,400	+65%	+$99.6K	﹤0.01%	1060
2024 Q2	$123K	Sell	28,340 -8,688	-23%	-$44.1K	﹤0.01%	1331
2024 Q1	$157K	Hold	37,028	–	–	﹤0.01%	1289
2023 Q4	$139K	Sell	37,028 -5,000	-12%	-$17.2K	﹤0.01%	1269
2023 Q3	$156K	Hold	42,028	–	–	﹤0.01%	1107
2023 Q2	$167K	Buy	+42,028	New	+$208K	﹤0.01%	1118
2021 Q3	–	Sell	-35,939	Closed	-$247K	–	975
2021 Q2	$247K	Buy	35,939 +20,775	+137%	+$165K	﹤0.01%	792
2021 Q1	$151K	Buy	+15,164	New	+$160K	﹤0.01%	822

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lido Advisors's CRMD Position: Q2 2026 in Review

Lido Advisors reduced its CorMedix (CRMD) stake by 0.07% in Q2 2026, selling an estimated $261 and leaving 44,707 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #1671.

Lido Advisors first reported a position in CRMD in Q1 2021 and has held it in 15 quarters since. The position peaked at $582K in Q2 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Lido Advisors held 44,707 shares of CorMedix worth $351K as of Q2 2026.
Lido Advisors sold 33 CorMedix shares in Q2 2026, an estimated $261.
CorMedix made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1671 holding.
Lido Advisors first reported a position in CorMedix in Q1 2021 and has held it in 15 quarters since.
Lido Advisors's CorMedix position peaked at $582K in Q2 2025.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.